Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Tolerx, Inc.

http://www.tolerx.com

Latest From Tolerx, Inc.

Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I

The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Review Pathway

China Releases Cosmetic Safety Assessment Guidelines, Other Draft CSAR Subsidiary Regs

As expected, the National Medical Products Administration has issued four draft subsidiary regulations in rapid succession since publishing China’s new, finalized framework regulation for cosmetic products at the end of June. The documents include Technical Guidelines for Cosmetic Safety Assessment, a topic on which industry has been eagerly awaiting clarity.

China Beauty

Unilever H1 Benefits From Sanitizer Blitz; Leadership Expects Lasting Hygiene ‘Preoccupation’

Unilever’s leadership is optimistic about its enormously expanded hygiene business – both skin cleansing and home cleaning – inasmuch as it doubts that a full COVID-19 recovery is in sight. The firm launched hand sanitizers in 65 new markets in just five months, helping to offset plunging sales in other areas of its business that were heavily impacted by lockdowns around the world.

Coronavirus COVID-19 Sales & Earnings

Interview: Why Biotech Companies Should Be Confident About Deals Despite Coronavirus

Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.

Deals Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register